hotspot -WSS

hotspot

author：explore 2025-09-29 20:00:11 - browse：25538

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Surgeons perform first xenotransplant using CRISPR'd pig kidney

WSS

Obesity now affects over 1 billion people worldwide, study finds

Covid isolation guidance eased by the CDC

Obesity now affects over 1 billion people worldwide, study finds

6 surprising facts about sugar

Testing GLP

CRISPR technology availability, affordability needs to be expanded

hotspot

hotspot

The next ALS data readout — overdue but important

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Congress gives doctors Medicare pay bump

United colonoscopy coverage change 'may cost lives,' doctors say

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Bright Health sells Medicare Advantage business to Molina

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Trump demands the U.S. pay no more for drugs than other countries … again

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

explore

With Wegovy coverage, Medicare patients may face high costs

'Patient friction coefficient' can gauge a clinical trial's patient burden

Flu vaccine offering decent levels of protection this winter, new data show

Bring on the sabbaticals for nurses

How to fix the rural physician shortage in the U.S.

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

entertainment

explore

hotspot

focus